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A large proportion of patients with carcinoma of the lung may benefit from the use of
radiation therapy. Operable patients have not been shown to benefit from preoperative irradia-
tion, but postoperative irradiation has improved survival in those found to have involvement of
hilar or mediastinal lymph nodes. Radiation therapy is the only potentially curative treatment
for patients who are inoperable, but do not have distant metastasis. Control of the local tumor
is very dependent upon dose-fractionation-time relationships. Patients who are relatively
asymptomatic, i.e., they have a high performance status, are curable if treated promptly with
radiation therapy. Small cell carcinoma requires both radiation therapy and chemotherapy. The
optimal method of combining the two modalities is yet to be determined, but prophylactic
cranial irradiation is necessary to control microscopic metastases that are not affected by
systemic chemotherapy, and thoracic irradiation is necessary to give the highest probability of
control of the primary tumor. Prophylactic cranial irradiation has also been shown to reduce
the frequency of brain metastasis in patients with squamous carcinoma, large cell carcinoma,
and adenocarcinoma; it may become more important in these cell types when more effective
chemotherapy is developed.
A large proportion of patients with cancer of the lung will require treatment with
radiation therapy some time during the course of the disease. For patients who are
operable, irradiation might be considered before or after resection. Patients who have
locally advanced disease or who are medically inoperable, receive irradiation alone or
in combination with chemotherapy as the definitive approach to their disease.
Approximately half of all patients with carcinoma of the lung present with distant
metastases and require radiation therapy for the palliation ofdistressing symptoms.
The palliative role of radiation therapy is well-recognized and is widely utilized. It
will not be discussed further as the emphasis in what follows is on the role of
radiation therapy in patients with localized disease.
RADIATION THERAPY IN PATIENTS WITH OPERABLE
CARCINOMA OF THE LUNG
Candidates for definitive treatment by resection include those with Stage I and
Stage II squamous cell, large cell, and adenocarcinoma, whose pulmonary function
will permit a lobectomy or pneumonectomy. For such patients, irradiation might be
considered as a preoperative or postoperative adjuvant to resection. Preoperative
irradiation was justified on the basis of short-term studies which showed apparent
195
Presented at the Symposium on Pulmonary Neoplasms: Review ofCurrent Status, VA Medical Center,
West Haven, CT, July 30-August 1, 1980.
Address reprint requests to: James D. Cox, M.D., Radiation Therapy, The Medical College of
Wisconsin, 8700 West Wisconsin Avenue, Milwaukee, WI 53226
Copyright © 1981 by The Yale Journal of Biology and Medicine, Inc.
All rights of reproduction in any form reserved.sterilization of tumor in resected specimens after irradiation [1]. A national coopera-
tive trial of the Veterans Administration Surgical Adjuvant Group was undertaken
on this basis. More than 90 percent of the patients were treated with conventional X-
irradiation as this study was conducted before most institutions had supervoltage
equipment. Furthermore, patients with small cell carcinoma were included in the
trial. The results showed a similar survival for patients who actually underwent
resection following the irradiation compared to those with resection alone. The
radiation therapy was associated with a higher complication rate, and the investiga-
tors concluded that preoperative irradiation did not contribute favorably to the
outcome of patients with carcinoma of the lung [2].
Postoperative irradiation should be considered in any patient where the risk of
microscopic residual disease is high. Patients with squamous cell carcinoma who
have undergone a "curative" resection are more likely than patients with the other cell
types to have persistent local disease without evidence of distant metastases [3]. To
date, there is no evidence to suggest any benefit from postoperative irradiation for
patients who are free of regional lymph node metastases. In fact, one study [4]
showed a decreased survival in patients with negative nodes who received postopera-
tive irradiation. Patients with metastases in para-bronchial, hilar, and mediastinal
lymph nodes have an increased probability of long-term survival if they receive
postoperative irradiation [5,6,7,8]. An ongoing randomized trial of the EORTC [9]
shows a slight survival advantage for irradiated patients with positive lymph nodes,
but it is not statistically significant. However, this trial does not show any disadvan-
tage in survival for patients with negative nodes who received postoperative irradia-
tion.
The oft-quoted work of Smart [10] confirmed the ability of radiation therapy to
control localized tumors that otherwise would have been operable. As will be
apparent from results in patients with inoperable disease, there is little doubt that
irradiation can control limited intrathoracic tumors. However, at present, there is no
reason to prefer irradiation to resection except for patients whose pulmonary
function would not permit the appropriate operation.
IRRADIATION FOR PATIENTS WITH INOPERABLE
CANCER OF THE LUNG
Effective irradiation of patients with inoperable or unresectable bronchial carci-
noma, in addition to providing palliation, prolongs survival. Ifthe tumor in the chest
is controlled, the median survival is doubled [11]. Higher doses of irradiation are
associated with the higher probability of local control [1 1]. As confirmation that the
local tumor is a major determinant of survival, increasing doses of irradiation have a
direct correlation with increased survival [12]. There is a natural concern that higher
doses of irradiation might lead to more damage of the normal lung. However,
morbidity from irradiation is more a function ofthe volume irradiated than the dose.
Doses above 2,500 rad in 21/2 weeks consistently produce pneumonitis and subsequent
scarring within the irradiated volume. The utilization of individualized blocks that
protect all normal lung possible (Fig. IA) permits high doses of irradiation to be
delivered to a restricted volume with a minimum of late effects (Fig.1B). The
additional justification for definitive irradiation in patients with inoperable but
localized disease is the finite curability of such patients. Several authors
[13,14,15,16,17] have reported three-year survival rates between 7 and 12 percent.
With a more selected patient population, careful, high-dose irradiation results in a
higher probability of survival. In a group of 197 patients with histologically or
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E FIG. IA. Treatment volume for a 61-year-old ...............woman with large cell carcinoma compressing
trachea and right upper lobe bronchus. Minimum
tumor dose was 6,300 rad in 35 fractions in seven
weeks (maximum dose in spinal cord limited to
4,500 rad in five weeks by use of oblique fields).
cytologically confirmed carcinoma of the lung of all cell types [18], short-term
survival was related to the ability to control the intrathoracic disease. Among the 92
patients with a performance status of 80 to 100 patients, those whose intrathoracic
tumor was controlled had a five-year disease-free survival rate of 22 percent. No
patient with persistent or recurrent thoracic disease lived beyond 27 months [19].
FIG. IB. Chest film three years after treatment;
patient is free of any evidence of cancer.
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Small cell carcinoma of the lung has been recognized for many years to be
strikingly responsive to irradiation. It is also very responsive to chemotherapy, and
very effective drug combinations have been developed in the past decade [20]. The
literature that has developed in the past decade is too vast to review in detail. The
impressive responses to chemotherapy led to theassumption that thoracic irradiation
was unnecessary. This assumption was tested in a prospective trial with highly
effective chemotherapy in which thoracic irradiation was withheld unless there was
failure of complete response or recurrence after complete response. Local recurrences
developed in 48 percent of these patients [21]. It is apparent that thoracic irradiation
is essential at some point in the management of patients with localized small cell
carcinoma, and the same can be said for patients with disseminated disease who
respond completely. An interaction of the thoracic irradiation with chemotherapy
has been demonstrated [22]. Relatively low doses of irradiation that would be
ineffective alone are able to control the thoracic disease when combined with effective
chemotherapy. With adequate irradiation in combination with chemotherapy, the
local recurrence rate can be reduced to 15 percent.
The importance of dissemination of small cell carcinoma to the central nervous
system has been recognized, but the magnitude of the problem has been underesti-
mated. The lengthening survival of patients with small cell carcinoma because of
effective chemotherapy has resulted in a much higher rate of spread to the CNS than
even autopsy studies would have suggested [23]. Prophylactic cranial irradiation,
with doses between 2,500 and 3,000 rad in two weeks, has reduced the frequency of
brain metastasis in several series [24]. A comparison of the risk of brain metastasis
related to survival and the use of prophylactic cranial irradiation shows that the
probability of brain metastasis does not continue to rise as patients live longer in the
prophylactically treated group (Fig. 2). This indicates that the microscopic amounts
of tumor are completely eliminated.
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PROPHYLACTIC CRANIAL IRRADIATION FOR ALL CELL TYPES
Prophylactic cranial irradiation (PCI) has become a standard part of the manage-
ment of patients with small cell carcinoma in most institutions. The risk of brain
metastasis has become fully apparent in patients with small cell carcinoma, but it has
only recently been recognized as a problem of equal magnitude in patients with large
cell carcinoma and adenocarcinoma[25]. A recently completed, randomized prospec-
tive trial of the Veterans Administration Lung Group investigated the role of PCI in
conjunction with thoracic irradiation, without chemotherapy, in patients with
carcinoma of the lung of all cell types. The dose used was 2,000 rad in 10 fractions in
two weeks. This dose, in the absence of chemotherapy, did not significantly reduce
the frequency of brain metastasis in patients with small cell carcinoma. However,
patients with "non-small cell" carcinoma did have a statistically significant reduction
(p = .038) in the frequency of brain metastasis for patients who received PCI [26].
Therefore, there may be an increasingly important role for prophylactic cranial
irradiation in patients with these cell types.
CONCLUSION
The role of radiation therapy in the current management of patients with
carcinoma of the lung is evolving and expanding. In addition to a beneficial effect for
patients with distressing symptoms, irradiation also has a role in operable patients
and those who are inoperable but still have localized disease. Patients with resectable
disease who are found to have involvement of regional lymph nodes benefit from the
systematic administration of postoperative irradiation. Patients with inoperable but
localized disease have a prolongation ofsurvival from thoracic irradiation, a survival
which is closely associated with the dose of irradiation administered; a small
proportion ofthese patients can be cured. The consistent use ofthoracic irradiation is
also important in the management of patients with small cell carcinoma, as is
prophylactic cranial irradiation; when combined with effective chemotherapy, the
prospects for long-term disease-free survival for patients with small cell carcinoma
are improving.
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